About this trial
Spinal cord injury (SCI) results in lower limb muscle loss, bone loss, and high fat mass that impede the recovery of physical function, increase bone fracture risk, and worsen health and quality of life. These deficits result from reduced activity after SCI and may be worsened by low testosterone, which is present in many men with SCI. In older men with low testosterone who do not have SCI, testosterone therapy (TRT) is known to increase muscle mass, muscle strength, and bone mineral density, and to reduce body fat. However, it is not known if TRT is effective in men with SCI. The purposes of this study are to determine the effectiveness of TRT in men who have low testosterone and difficulty walking after chronic motor incomplete SCI and to assess whether a process in the body that changes testosterone to dihydrotestosterone (DHT; another hormone that is stronger than testosterone) impacts the effectiveness of TRT in the impaired lower limbs and in other tissues after SCI. The researchers hypothesize that TRT will improve muscle and bone in the impaired limbs of men with chronic incomplete SCI and reduce fat mass, and that finasteride (a drug that blocks that blocks a process that changes testosterone to DHT) will influence prostate symptoms but not the musculoskeletal or body composition benefits produced by TRT.
Eligibility criteria
Qualifiers
Veterans eligible for care within the Veterans Health Administration (VHA)
Diagnosis of motor incomplete SCI (AIS C-D) for >24-months involving spinal segment lumbar (L)1 or above from trauma, vascular, or orthopedic pathology
Low total testosterone (<300 nanograms/decilliter [ng/dL]) and/or low free testosterone (<4.6 ng/dL)
decreased energy
Disqualifiers
Involvement in another research study that may influence outcomes
Mental state that precludes understanding the protocol
Life expectancy <12 months
History of or current congenital spinal cord injury (SCI) (e.g., Chiari malformation, myelomeningocele, intraspinal neoplasm, Friedreich's ataxia) or degenerative spinal disorder (e.g., spinocerebellar degeneration) that may complicate procedures
Trial design
Treatments tested in this trial
- testosterone cypionate
- finasteride
- placebo injection
- placebo pill
Treatment groups
Sponsors and collaborators
VA Office of Research and Development
Lead sponsor
North Florida/South Georgia Veterans Health System
Collaborator
VA Eastern Colorado Health Care System
Collaborator
University of Colorado, Denver
Collaborator
James J. Peters Veterans Affairs Medical Center
Collaborator
James A. Haley Veterans Administration Hospital
Collaborator